2 Under-the-Radar Stocks That Have Soared This Year

TransMedics Group's Organ Care System (OCS) is driving material adoption and better clinical outcomes—lung utilization was 87% with OCS versus 23% with cold storage—supporting Q3 revenue of $143.8m (+32% y/y) and EPS of $0.66 versus $0.12 a year ago; expansion of its National OCS Program (in‑house air/ground transport), a Mercedes‑Benz ground‑transport partnership in Italy, international rollouts and development of next‑generation OCS for additional organs (e.g., kidneys) are clear near‑ and medium‑term growth catalysts. France‑based Abivax posted positive phase‑3 results for obefazimod in moderate‑to‑severe ulcerative colitis—including remission in a cohort where 47.3% had failed prior therapies—setting up a potential U.S. filing in H2 2026 and plans to pursue Crohn’s, but the stock has rallied >1,000% YTD to an elevated ~€7.5bn valuation and remains exposed to regulatory and clinical risk. Both names therefore represent high‑risk, high‑reward opportunities for investors focused on healthcare innovation and commercialization execution.

Analysis

TransMedics Group's Organ Care System (OCS) is driving measurable clinical and commercial differentiation: lung utilization was 87% with OCS versus 23% with cold storage, the OCS reduces post‑transplant complications, and Q3 revenue was $143.8 million (up 32% year‑over‑year) with EPS of $0.66 versus $0.12 a year earlier. These operating metrics and the demonstrable reduction in organ waste underpin the company's current revenue acceleration and justify continued investor interest in its core product.

Operational expansion is a clear near‑term growth vector: TransMedics is scaling its National OCS Program (in‑house organ procurement and air/ground logistics), has struck a Mercedes‑Benz ground‑transport partnership in Italy, and is pursuing international rollouts; development of a next‑generation OCS targeting additional organs such as kidneys represents a medium‑term upside catalyst. Management's expectation of steady growth in transplant volumes provides a favorable demand backdrop but execution risk on logistics and commercialization remains.

Abivax reported statistically significant phase‑3 remission results for obefazimod in moderate‑to‑severe ulcerative colitis, with 47.3% of study patients having inadequate responses to prior therapies; the company plans a U.S. regulatory submission in H2 2026 contingent on an ongoing maintenance trial. The stock has rallied over 1,000% year‑to‑date to an implied valuation of €7.5 billion (~$8.7 billion), leaving considerable upside priced for success but material downside if regulatory or trial outcomes falter; overall sentiment in the article is moderately positive while market impact is described as modest.

Key Decisions for Investors

• For TransMedics (TMDX) consider accumulating on disciplined pullbacks given 32% y/y revenue growth and strong OCS clinical differentiation, but size positions to reflect execution risk and monitor NOP rollout KPIs (utilization rates, transport capacity) and international partnership progress
• Treat TransMedics' next‑generation OCS and kidney indication as a material medium‑term catalyst; reduce exposure if development milestones or commercial adoption lag expectations
• For Abivax (ABVX) limit allocation to risk‑tolerant capital and wait for the maintenance trial confirmation and the planned U.S. submission in H2 2026 before adding material exposure, because the >1,000% YTD rally and ~€7.5bn valuation price in significant positive regulatory outcomes
• Use position sizing, explicit stop levels or hedges around regulatory and clinical catalysts for both names and monitor upcoming revenue/EPS prints for TMDX and clinical/regulatory readouts for ABVX as primary re‑assessment triggers